Portal de investigación
- Inicio
- Proyectos y Estudios
- ESTUDIO MULTICÉNTRICO, ALEATORIZADO, CON DOBLE ENMASCARAMIENTO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS SEGUIDO DE UNA EXTENSIÓN ABIERTA PARA EVALUAR LA EFICACIA Y SEGURIDAD DE FREMANEZUMAB PARA EL TRATAMIENTO PREVENTIVO DE LA MIGRAÑA EN PACIENTES CON TRASTORNO DEPRESIVO MAYOR.
ESTUDIO MULTICÉNTRICO, ALEATORIZADO, CON DOBLE ENMASCARAMIENTO, CONTROLADO CON PLACEBO Y DE GRUPOS PARALELOS SEGUIDO DE UNA EXTENSIÓN ABIERTA PARA EVALUAR LA EFICACIA Y SEGURIDAD DE FREMANEZUMAB PARA EL TRATAMIENTO PREVENTIVO DE LA MIGRAÑA EN PACIENTES CON TRASTORNO DEPRESIVO MAYOR.
Datos básicos
- Código:
- TV48125-MH-40142
- Protocolo:
- TV48125-MH-40142
- EUDRACT:
- 2019-001989-15
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- 2020
- Año de finalización:
- 2022
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&R
Resultados del Ensayo Clínico
1st Post-European Headache Federation Meeting: a review of the latest developments presented at the 2020 European Headache Federation Congress
Lainez, JM; (...); Silberstein, S
Review. 10.33588/rn.72s02.2021155. 2021
Calcitonin gene-related peptide in migraine: from pathophysiology to treatment.
Santos-Lasaosa S; (...); Pozo-Rosich P
Article. 10.1016/j.nrleng.2019.03.025. 2022
Document of revision and updating of medication overuse headache (MOH).
González-Oria C; (...); Santos-Lasaosa S
Review. 10.1016/j.nrl.2020.04.029. 2021
Epilepsy, status epilepticus, and hemiplegic migraine coexisting with a novel SLC4A4 mutation.
Gil-Perotín S; (...); Díaz S
Article. 10.1007/s10072-020-04961-x. 2021
Erenumab vs galcanezumab in a very difficult-to-treat migraine population. Efficacy and safety
Samuel, DI; (...); Jose, NMM
Meeting Abstract. 2021
Erenumab vs galcanezumab in a very difficult-to-treat migraine population. Efficacy and safety
Samuel, DI; (...); Jose, NMM
Meeting Abstract. 2021
The Humanistic Disease Burden of Episodic and Chronic Migraine in France, Spain and the United Kingdom
Diaz-Insa, S; (...); Goadsby, PJ
Meeting Abstract. 2020
THE HUMANISTIC DISEASE BURDEN OF EPISODIC AND CHRONIC MIGRAINE IN FRANCE, SPAIN AND THE UNITED KINGDOM
Diaz-Insa, S; (...); Goadsby, PJ
Meeting Abstract. 2020
Treatment failure with anti-CGRP therapy: should we discontinue the treatment or switch it?
Castellanos, CN; (...); Insa, SD
Meeting Abstract. 2021
Treatment failure with anti-CGRP therapy: should we discontinue the treatment or switch it?
Castellanos, CN; (...); Insa, SD
Meeting Abstract. 2021
Which patient related outcome best reflects the willing of a patient to continue with an anti-CGRP monoclonal preventive treatment? A sub-analysis of a prospective study
Castellanos, CN; (...); Insa, SD
Meeting Abstract. 2021